We are live on ! Find out more
AVAI

Atlas Venture Associates IX Portfolio holdings

AUM $11.8M
1-Year Est. Return 58.35%
This Fund
S&P 500
This Quarter Est. Return
-24.65%
1 Year Est. Return
-58.35%
3 Year Est. Return
-89.8%
5 Year Est. Return
-87.69%
10 Year Est. Return
–
AUM
$113M
AUM Growth
-$28.7M
Cap. Flow
+$16.9M
Cap. Flow %
14.97%
Top 10 Hldgs %
100%
Holding
4
New
1
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
SPRO icon
Spero Therapeutics
SPRO
+$16.9M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 98.06%
2 Communication Services 1.94%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NTLA icon
1
Intellia Therapeutics
NTLA
$1.5B
$68.8M 60.94%
3,579,788
– –
SYBX
2
DELISTED
Synlogic
SYBX
$25.7M 22.78%
176,798
– –
SPRO icon
3
Spero Therapeutics
SPRO
$71.8M
$16.2M 14.33%
+1,376,968
New +$16.9M
SNAP icon
4
Snap
SNAP
$7.99B
$2.19M 1.94%
150,160
– –

Similar funds

EEPIS
Evolution Equity Partners II SARL Luxembourg $11.8M AUM 63.6% 1-Year Est. Return
LM
Lockheed Martin Bethesda, Maryland $12.1M AUM 46.13% 1-Year Est. Return
HMP9
Highland Management Partners 9 Cambridge, Massachusetts $12.6M AUM 85.13% 1-Year Est. Return
TCSAM
Tyrus Capital S.A.M. Monaco $10.5M AUM 4.88% 1-Year Est. Return
AEM
ACON Equity Management Washington, District of Columbia $13.8M AUM 62.17% 1-Year Est. Return
PT
Palantir Technologies Denver, Colorado $9.72M AUM 6.46% 1-Year Est. Return
AR
Acacia Research New York $14.1M AUM 50.98% 1-Year Est. Return
MM
Malka Meyer $8.77M AUM 64.77% 1-Year Est. Return

Atlas Venture Associates IX's Q4 2017 Portfolio in Review

As of Q4 2017, Atlas Venture Associates IX held 4 positions worth $113M, down 20% from $142M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Atlas Venture Associates IX deployed $16.9M of net new capital in Q4 2017, opening 1 new position. Its largest new stake was Spero Therapeutics: 1,376,968 shares worth $16.2M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 98% a quarter earlier, followed by Communication Services.

  • Atlas Venture Associates IX's largest Q4 2017 buy was Spero Therapeutics: 1,376,968 shares worth $16.2M.
  • Atlas Venture Associates IX's ten largest holdings make up 100% of its $113M portfolio in Q4 2017.
  • Atlas Venture Associates IX opened 1 new position and closed 0 in Q4 2017.
  • Atlas Venture Associates IX's portfolio value fell 20% quarter-over-quarter to $113M.

Based on Atlas Venture Associates IX's 13F filing for Q4 2017, filed 5 Feb 2018.